# Chen Jie

> Chen Jie is a seed investor at BioVenture backing Medical, Health Care and Biopharma. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [BioVenture](https://shizune.co/investors/profile/bioventure)
- Total investments: 5
- Last investment: Jun 2025
- Lead investor: 80%
- Last updated: Aug 2026

Chen Jie is a seed investor at BioVenture focused on Medical and Health Care. Chen Jie

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 4 | 80% |
| Health Care | 3 | 60% |
| Biopharma | 2 | 40% |
| Biotechnology | 2 | 40% |
| Training | 1 | 20% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 40% |
| Series A | 2 | 40% |
| Series B | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 4 | 80% |
| United States | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Xiaolu Biotech | Xiaolu Bio is a biopharmaceutical developer that focuses on the research and development of innovative drugs for autoimmune and inflammatory diseases. |  | Seed | Jun 17, 2025 |  |
| Sanegene Bio | Sanegene Bio is currently operating in stealth mode. | $80M | Series A | Dec 01, 2023 |  |
| Ruoyi Biotech | Ruoyi Biotech is a developer of macromolecular drug delivery technology. |  | Seed | Mar 18, 2023 |  |
| Reforgene Medicine | Reforgene Medicine is a biomedical company that uses gene editing and genomic technology to develop new drugs intended to cure genetic diseases. |  | Series A | Sep 16, 2021 |  |
| Dami&Xiaomi | Rice and millet is China's leading platform services for children with autism spectrum, from 2014 Nian 9 Yue Jiang Ying Shuang (rice) founded the "rice and millet" micro-channel public number. It now provides integrated services such as rehabilitation services, integrated education support, parent training, online courses, andpopular science information. | $13.6M | Series B |  |  |

5 of 5 investments shown.

## Co-investors
- [Oriza Holdings](https://shizune.co/investors/profile/oriza-holdings) — VC Fund, 2 deals together
- [Alwin Capital](https://shizune.co/investors/profile/alwin-capital) — VC Fund, 1 deal together
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 1 deal together
- [Boquan Equity Investment Management](https://shizune.co/investors/profile/boquan-equity-investment-management) — VC Fund, 1 deal together
- [China Merchants Securities](https://shizune.co/investors/profile/china-merchants-securities) — VC Fund, 1 deal together
- [Dongjiu Xinyi Capital](https://shizune.co/investors/profile/dongjiu-xinyi-capital) — VC Fund, 1 deal together

## About BioVenture

VC Fund · Suzhou, China

Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.

5 contacts available at BioVenture.

| Name | Title | Profile |
| --- | --- | --- |
| Erik Hoppe | Executive Partner | https://shizune.co/investors/profile/erik-hoppe |
| Chen Jie | Founding Partner | https://shizune.co/investors/profile/chen-jie-281b |
| Gaojian Ning | Investment Director | https://shizune.co/investors/profile/gaojian-ning |
| Haihua Huang | Investment Director | https://shizune.co/investors/profile/haihua-huang |
| Jacky Chen | General Manager | https://shizune.co/investors/profile/jacky-chen |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Chen Jie invest in?

Chen Jie invests primarily in Medical, Health Care and Biopharma startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chen Jie last invest?

The most recent investment recorded for Chen Jie closed in Jun 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co